Key result
Carvedilol shows comparable three-year mortality to bisoprolol in STEMI patients with mid-range LVEF.
Why the study?
The comparative long-term outcomes of carvedilol versus bisoprolol in STEMI patients with mid-range LVEF (40% to 49%) treated with DESs were unclear.
Does carvedilol reduce all-cause death compared to bisoprolol in STEMI patients with mid-range LVEF treated with drug-eluting stents?
Cohort (n=5,285)
Yes
Does carvedilol reduce all-cause death compared to bisoprolol in STEMI patients with mid-range LVEF treated with drug-eluting stents?
Effect estimate: HR 0.859 (95% CI 0.661-1.117)
Absolute Event Rate: 4.1% vs 4.8%
p-value: p=0.286
In STEMI patients with mid-range LVEF treated with drug-eluting stents, carvedilol and bisoprolol demonstrated comparable long-term clinical outcomes for all-cause death and MACE up to 3 years.
No takes yet. Share an insight, caveat, or question.
Comparable mortality supports either β-blocker in mid-range LVEF STEMI; hypothesis-generating and should not change practice without RCTs.
Susanti et al. (2025) conducted a cohort in ST-segment elevation myocardial infarction (STEMI) with mid-range LVEF (n=5,285). Carvedilol vs. Bisoprolol was evaluated on All-cause death (HR 0.859, 95% CI 0.661-1.117, p=0.286). Carvedilol and bisoprolol showed comparable rates of all-cause death at 3 years in STEMI patients with mid-range LVEF (4.1% vs 4.8%; HR 0.859; 95% CI 0.661-1.117; P=0.286).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: